Download PDF
Semin Thromb Hemost 2004; 30(6): 673-681
DOI: 10.1055/s-2004-861510
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Contemporary Management of ST Elevation Myocardial Infarction

Barry S. Weinstock1
  • 1Piedmont Hospital, Atlanta, Georgia
Further Information

Publication History

Publication Date:
04 January 2005 (online)

    Permissions and Reprints

ABSTRACT

Management of acute ST elevation myocardial infarction (MI) has become increasingly complex. Third-generation fibrinolytic agents have provided simpler bolus administration and enhanced arterial patency rates but have not lowered mortality. Prehospital fibrinolysis reduces time to treatment, and studies continue to better define the clinical benefits. Combining glycoprotein (GP) IIb/IIIa inhibitors with reduced-dose fibrinolytic therapy thus far has not reduced mortality; improvements in secondary outcomes such as recurrent infarction have been offset by increases in bleeding complications, particularly in elderly patients. In contrast to fibrinolytic trial results, outcomes are improved in patients who promptly undergo primary percutaneous coronary intervention (PCI). Meta-analyses demonstrate a significant reduction in mortality compared with patients who receive fibrinolytic therapy. Accessibility of primary intervention remains an important limitation, although recent trials suggest superiority of intervention even when hospital transfer is necessary. Conflicting trends include the development of regional centers for interventional treatment of MI as well as the dissemination of limited interventional programs to smaller hospitals. Facilitated PCI, a hybrid of pharmacological reperfusion (typically combination therapy) followed by intervention, may bridge the delay when primary intervention is not immediately available. Optimal therapy for acute MI must be individualized based on both patient characteristics and resource availability.

KEYWORDS

Myocardial infarction - fibrinolytic therapy - glycoprotein IIb/IIIa inhibitors - percutaneous coronary intervention - PCI - fibrinolytic agents

REFERENCES

  • 1 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators.  N Engl J Med. 1993;  329 673-682
    CrossrefPubMedGoogle Scholar
  • 2 A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.  N Engl J Med. 1997;  337 1118-1123
    CrossrefPubMedGoogle Scholar
  • 3 Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators.  Lancet. 1999;  354 716-722
    CrossrefPubMedGoogle Scholar
  • 4 Topol E J. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial.  Lancet. 2001;  357 1905-1914
    CrossrefPubMedGoogle Scholar
  • 5 Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction . Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).  Lancet. 1986;  1 397-402
    PubMedGoogle Scholar
  • 6 In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.  Lancet. 1990;  336 71-75
    CrossrefPubMedGoogle Scholar
  • 7 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.  Lancet. 1988;  2 349-360
    PubMedGoogle Scholar
  • 8 Smalling R W, Bode C, Kalbfleischet J et al.. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction.  Circulation. 1995;  91 2725-2732
    PubMedGoogle Scholar
  • 9 Bode C, Smalling R W, Berg G et al.. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.  Circulation. 1996;  94 891-898
    PubMedGoogle Scholar
  • 10 Gibson C M, Cannon C P, Murphy S A et al.. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B Trial.  Am J Cardiol. 1999;  84 976-980
    CrossrefPubMedGoogle Scholar
  • 11 Antman E M, Gibson C M, de Lemos J A et al.. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14.  Eur Heart J. 2000;  21 1944-1953
    CrossrefPubMedGoogle Scholar
  • 12 Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.  Circulation. 2000;  101 2788-2794
    PubMedGoogle Scholar
  • 13 Brener S J, Zeymer U, Adgey A et al.. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) Trial.  J Am Coll Cardiol. 2002;  39 377-386
    PubMedGoogle Scholar
  • 14 Giugliano R P, Roe M, Harrington R et al.. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) phase II angiographic Trial.  J Am Coll Cardiol. 2003;  41 1251-1260
    CrossrefPubMedGoogle Scholar
  • 15 Weaver W D, Cerqueira M, Hallstrom A P et al.. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial.  JAMA. 1993;  270 1211-1216
    CrossrefPubMedGoogle Scholar
  • 16 Morrow D A, Antman E M, Sayah A et al.. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of the Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 Trial.  J Am Coll Cardiol. 2002;  40 71-77
    CrossrefPubMedGoogle Scholar
  • 17 American Heart Asociation 2002; Oral Presentation and www.clinicaltrialresults.org. 
    Google Scholar
  • 18 de Bono D P. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.  J Am Coll Cardiol. 1988;  12(6 Suppl A) 20A-23A
    PubMedGoogle Scholar
  • 19 Topol E J, Califf R M, Kereiakes D J, George B S. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial.  J Am Coll Cardiol. 1987;  10(5 Suppl B) 65B-74B
    PubMedGoogle Scholar
  • 20 O'Neill W W, Weintraub R, Grines C L et al.. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction.  Circulation. 1992;  86 1710-1717
    PubMedGoogle Scholar
  • 21 Grines C L, Browne K F, Marco J et al.. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction.  N Engl J Med. 1993;  328 673-679
    CrossrefPubMedGoogle Scholar
  • 22 Zijlstra F, de Boer M J, Hoorntje J et al.. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.  N Engl J Med. 1993;  328 680-684
    CrossrefPubMedGoogle Scholar
  • 23 Weaver W D, Simes R J, Betriu A et al.. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.  JAMA. 1997;  278 2093-2098
    CrossrefPubMedGoogle Scholar
  • 24 Grines C L, Cox D A, Stone G W et al.. Coronary angioplasty with or without stent implantation for acute myocardial infarction.  N Engl J Med. 1999;  341 1949-1956
    CrossrefPubMedGoogle Scholar
  • 25 Zhu M M, Feit A, Chadow H et al.. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials.  Am J Cardiol. 2001;  88 297-301
    CrossrefPubMedGoogle Scholar
  • 26 Andersen H R. The Danish multicenter randomized trial on thrombolytic therapy versus acute coronary angioplasty in acute myocardial infarction. Presented at the American College of Cardiology's 51st Annual Scientific Session Atlanta, GA; March 2002
    Google Scholar
  • 27 Aversano T, Aversano L T, Passamani E et al.. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial.  JAMA. 2002;  287 1943-1951
    CrossrefPubMedGoogle Scholar
  • 28 Brener S J, Barr L A, Burchenalet J E et al.. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction.  Circulation. 1998;  98 734-741
    PubMedGoogle Scholar
  • 29 Montalescot G, Barragan P, Wittenberg O et al.. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
    CrossrefPubMedGoogle Scholar
  • 30 Antionucci D. Abciximab carbostent evaluation. Presented at the TCT 14th Annual Symposium in Washington, D.C. September 24-29, 2002
    Google Scholar
  • 31 Kaul U, Gupta R K, Haridas K K et al.. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.  Catheter Cardiovasc Interv. 2002;  57 497-503
    PubMedGoogle Scholar
  • 32 Hermann H C, Moliterno D J, Ohman E M et al.. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction.  J Am Coll Cardiol. 2000;  36 1489-1496
    CrossrefPubMedGoogle Scholar

Barry S WeinstockM.D. 

4409 Belvedere Close

Marietta, GA 30067

Email: heartdoc@mindspring.com

      >